TheraRadar
Data updated: May 26, 2026

ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE (abacavir sulfate)

Infectious Disease Approved 2013-12-05
Jump to: Indications Approvals Trials Competitors Safety Patents
1
Indication
--
Phase 3 Trials
12
Years on Market

Details

Status
Discontinued
First Approved
2013-12-05
Routes
ORAL
Dosage Forms
TABLET

Companies

Lupin Viatris
Active Ingredient: ABACAVIR SULFATE , LAMIVUDINE , ZIDOVUDINE

ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE Approval History

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
6 FDA actions from 2013 to 2022
Apr 2022 SUPPL
Label · Labeling
Dec 2020 SUPPL
Label · Labeling
Dec 2013 ORIGINAL
Update
FDA Letter

What ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE Treats

1 FDA approvals

Originally approved for its first indication in 2013 .

  • Other (1)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

ClinicalTrials.gov ↗ Pro

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE FDA Label Details

Track ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

FDA Approval: ANDA202912 → Trials: ClinicalTrials.gov →

Data sourced from official FDA and NIH databases. Click links to verify on original sources.